February 28, 2018 / 5:48 PM / 9 months ago

BRIEF-Nanobiotix FY Revenue Down At ‍​0.3 Million Euros

Feb 28 (Reuters) - NANOBIOTIX SA:

* FY REVENUE EUR ‍​0.3 MILLION VERSUS EUR 1.6 MILLION YEAR AGO

* TO PRESENT RESULTS OF SOFT TISSUE SARCOMA PHASE II/III TRIAL WITH NBTXR3 IN Q2 2018‍​

* TO START IN Q2 2018 PHASE I/II CLINICAL TRIAL OF NBTXR3 ACTIVATED BY RADIOTHERAPY WITH ANTI-PD1 ANTIBODY IN CANCER PATIENTS‍​ Source text: bit.ly/2t1m1Gt Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below